Clinical trial
Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis
NCT03091400 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 16, 2017
- Completion date
- June 11, 2018
- Enrollment
- 11 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.